MIRAGEN THERAPEUTICS, INC. 4
4 · MIRAGEN THERAPEUTICS, INC. · Filed Jun 30, 2017
Insider Transaction Report
Form 4
Hughes Thomas E.
Director
Transactions
- Award
Stock Option (right to buy)
2017-06-28+12,000→ 12,000 totalExercise: $12.06Exp: 2027-06-27→ Common Stock (12,000 underlying)
Holdings
- 1,171
Stock Option (right to buy)
Exercise: $12.00Exp: 2027-03-23→ Common Stock (1,171 underlying) - 14,827
Common Stock
Footnotes (4)
- [F1]Reduced to correct the previously reported number of shares issued pursuant to a restricted stock award to 765 shares granted to the Reporting Person on March 24, 2017 and as previously reported on a Form 4 filed with the Securities and Exchange Commission (the "SEC") on March 28, 2017. The adjustment is due to a change in the final closing price of the Issuer's shares as reported on The NASDAQ Capital Market on the date of grant.
- [F2]Automatic non-discretionary grant to the Reporting Person of a nonstatutory stock option under the Issuer's 2016 Equity Incentive Plan (the "Plan") in accordance with the Issuer's Amended and Restated Non-Employee Director Compensation Policy. One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the next annual meeting of the Issuer's stockholders following the date of grant, subject in each case to the Reporting Person's continued service on such vesting date.
- [F3]Previously reported grant to the Reporting Person of a stock option under the Plan. The shares vest in three equal quarterly installments beginning on April 1, 2017 through December 31, 2017, provided that at the relevant vesting dates the Reporting Person's continuous service to the Issuer has not been terminated as defined in and as determined under the Plan. The option expires 10 years after the date of grant.
- [F4]Represents the corrected number of derivative securities beneficially owned pursuant to a stock option granted to the Reporting Person on March 24, 2017 and as previously reported on a Form 4 filed with the SEC on March 28, 2017. The adjustment is due to a change in the final closing price of the Issuer's shares as reported on The NASDAQ Capital Market on the date of grant.